F10 and ischemic stroke: Since their introduction into clinical routine, direct oral anticoagulants (DOACs) that inhibit thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, and edoxaban) have largely replaced warfarin as the first-hand choice to protect against ischemic stroke in patients with atrial fibrillation.